Preparation of mucoadhesive methacrylated chitosan nanoparticles for delivery of ciprofloxacin

Bio-inspired, programmable biomacromolecules based nanostructures driven cancer therapy

Cancer remains a significant global health challenge, driving the development of advanced platforms for highly targeted and efficient drug delivery. Early-stage nanocarriers, such as synthetic polymeric and inorganic materials, face limitations in biocompatibility and biodegradability. In contrast, bioinspired nanocarriers derived from natural biomacromolecules mimic biological processes and present a promising alternative due to their biocompatibility, biodegradability and non-toxicity. The effectiveness of these drug delivery systems is influenced by factors such as size, shape, surface properties, morphology, functionalization, and preparation methods. Various biomacromolecule-inspired nanocarriers such as protein-based, lipid-based, carbohydrate-based and nucleic acid-based are now at the forefront of research. This review highlights the properties, advantages and limitations of different bioinspired materials. We also explore cutting-edge approaches for cancer therapy using these nanocarriers with recent in-vitro, in-vivo and patent evidence. Finally, we address the challenges and potential solutions associated with bioinspired nanocarriers, proposing future directions. Overall, this review explores nature-inspired drug delivery systems that have paved the way for advancements in cancer therapy.

Antibacterial Lecithin/Chitosan Nanoparticles for the Sustained Release of Ciprofloxacin to Treat Ocular Bacterial Infections

Ocular drug-delivery is one of the most challenging areas owing to nature of ocular tissues. Various nanoformulations have been designed and investigated for drug-delivery to achieve high drug bioavailability. The major focus of these preparations available in market is to utilize nanomaterial as drug-carrier only, with less focus on developing functional-nanomaterials, which is a key knowledge gap in the field. To address this, we developed a nanoparticulate system from bioactive-polymers, having intrinsic antimicrobial and mucoadhesiveness, loaded with ciprofloxacin (cipro) to treat ocular bacterial infections. Cipro-loaded lecithin/chitosan nanoparticles were prepared and characterized for their physiochemical properties. They exhibited good drug loading efficiency and showed sustained drug-release for 72 h, with slow release for first 4 h followed by a burst release in phosphate buffered saline and simulated tear fluid. Cipro-loaded nanoparticles were assessed for their antibacterial potential against Staphylococcus aureus (96 %) and Pseudomonas aeruginosa (72 %) using optical density, disc-diffusion method, live-dead assay, and demonstrated promising antibacterial properties. The drug-loaded nanoparticles showed good cytocompatibility (~90 %) towards murine fibroblasts and rabbit corneal cells. Being amphiphilic in nature, the nanoparticles exhibited mucoadhesiveness, hemocompatibility (<4 %) and, thus, proving to be a promising candidate for treating ocular infections. This approach ensures efficient drug delivery and synergic/additive therapeutic effects.

Orally disintegrating films based on pullulan and HPMC with carbopol-coated mucoadhesive nanoparticles for dual-pattern drug release

Dual-pattern drug release systems are a new type of drug delivery system designed to achieve both immediate and sustained drug release. This study developed a dual-pattern system by combining orally disintegrating films (ODFs) with mucoadhesive nanoparticles (NPs). The NPs were made from silk fibroin (SF) coated with carbopol polymer (CP) and loaded with midazolam (MID) (MID-CP/SFNPs). MID was chosen for its rapid onset, high lipophilicity, and excellent bioavailability, making it ideal for buccal administration. The MID-CP/SFNPs had an average diameter of 260.3 nm, a negative zeta potential of -22 mV, and an 80.6 % encapsulation efficiency. When tested against rabbit buccal mucosa, the CP/SFNPs demonstrated excellent mucoadhesive properties. Using a casting process, the MID-CP/SFNPs were combined with polysaccharide films made from pullulan and hydroxypropyl methylcellulose (PUL/HPMC) containing MID. The final product, MID-CP/SFNPs@MID-ODFs, had a uniform thickness of 68.8 μm, a consistent drug content of 87.5 %, significant flexibility (219 times), and a suitable disintegration time of 16 s. This formulation showed a rapid initial drug release of 45.6 % within the first 30 min, followed by a sustained release, resulting in a total of 91 % of the drug being released over 20 h. Histological evaluations confirmed no adverse effects on the microscopic structure of the buccal mucosa. This innovative system, combining ODFs with mucoadhesive NPs, showed promising results, making it a viable candidate for biomedical applications.

Marine polysaccharides for antibiofilm application: A focus on biomedical fields

Microbial pathogens such as bacteria and fungi form biofilms, which represent substantial hurdles in treating human illness owing to their adaptive resistance mechanism to conventional antibiotics. Biofilm may cause persistent infection in a variety of bodily areas, including wounds, oral cavity, and vaginal canal. Using invasive devices such as implants and catheters contributes significantly to developing healthcare-associated infections because they offer an ideal surface for biofilm formation. Marine organisms produce a variety of polysaccharides, which have recently attracted worldwide attention due to their biochemical features, various applications, and advantageous properties such as bioactivity, biodegradability, and biocompatibility. Because of their antimicrobial and antibiofilm features, several polysaccharides such as chitosan, fucoidan, carrageenan, alginate, and hyaluronic acid have been used to treat infected wounds as well as ophthalmic, oral, and vaginal infections. In addition, marine polysaccharides are currently employed as coatings on medical devices and implant materials, alone or in combination with other bioactive substances or nanomaterials, to protect the materials' undertones from microbial contamination. This review discussed the recent advancements in marine polysaccharides and their derivatives as a therapeutic potential against biofilm-associated diseases. The potential obstacles in the scalability of their production, clinical translation, and/or regulatory hurdles have also been discussed.

In vitro and in vivo evaluation of tedizolid nanoparticle incorporated buccal films for oromucosal infections

A novel tedizolid phosphate (TZP) nanoparticle (NP)-loaded buccal film formulation was developed for the treatment of buccal wounds infected with S. aureus. TZP-loaded chitosan NPs were produced and characterized to prepare this composite system. The optimum NP formulation was then loaded into mucoadhesive buccal films. The antibacterial effects of the obtained buccal films were evaluated by in vitro and in vivo studies. The optimum TZP-NP formulation (F8) had a particle size of 177.40 ± 2.97 nm and PDI and ZP values were 0.437 ± 0.002 and 33.9 ± 0.5, respectively. In antibacterial efficacy tests, the optimum NP containing buccal film formulation was used, which released approximately 90 % of TZP within 5 h. TZP-NP-loaded buccal films achieved a 3 log10 reduction in S. aureus within just 3 h. It was also administered to Wistar albino rats with S. aureus-infected buccal wounds. As a result of in vivo studies, a significant decrease in the number of S. aureus was detected in wound samples treated with TZP-NP-loaded buccal films. In addition, a complete inhibition of growth was observed on the fifth day of the film application. The current work suggested that the TZP-NP-loaded composite films could be promising candidates for effective and long-acting antibacterial treatment of buccal wounds.

High-performance removal of methylene blue dye using porous lignin extracted from sugarcane bagasse by deep eutectic solvent

This study evaluated the ability of triethyl benzyl ammonium chloride/lactic acid deep eutectic solvent extracted lignin (TEBAC/LA-DES-L) to adsorb methylene blue (MB) without additional functional group modification. The structure and morphology of TEBAC/LA-DES-L were characterized using SEM, BET, FT-IR, and TGA techniques. Various factors influencing MB adsorption, such as extraction temperature, solution pH, adsorbent dose, initial MB concentration, adsorption time, and reaction temperature, were investigated. The Redlich-Peterson isotherm displayed a good fit for the experimental data, with a maximum adsorption capacity of 85.16 mg/g. Kinetic analysis suggested that the adsorption process followed the pseudo-second-order model, with adsorption occurring in <100 min on DES-L-4 h. The mechanism of MB adsorption on DES-L-4 h was attributed to electrostatic attraction, hydrophobic interactions, and hydrogen bonding forces. Overall, DES-L-4 h demonstrated high adsorption capacity and rapid adsorption rate, making it a promising adsorbent for effectively removing cationic dyes from wastewater.

A new methacrylate-chitosan based blend and its ZnO containing nanocomposites: Investigation of thermal and biological properties

Biobased materials are an important step towards a sustainable future. The need for these materials, which stand out in terms of their environmental and economic benefits, is increasing daily. This study includes the production of new bio based nanocomposites containing a blend of biopolymer chitosan (CS) and synthetic polymethacrylate derivative poly(2-oxo-2-(3,4,5-trifluoroanilino)ethyl-2-methylprop-2-enoate)(POTFAMA) and biosynthesized zinc oxide nanoparticles (ZnO NPs) by hydrothermal method. POTFAMA, POTFAMA-CS blend, and POTFAMA-CS/ZnO nanocomposites were characterized by FTIR, XRD, SEM, EDX, and TEM techniques. The thermal properties of the materials were determined by TGA and DSC. While POTFAMA reduced the thermal stability of CS, ZnO NPs incorporated into POTFAMA-CS blend increased the thermal stability. POTFAMA-CS blend had a single glass transition temperature (Tg) value at 116 °C. The Tg of CS, which was 93 °C, increased by 23 °C after blending with POTFAMA, and by 34 °C with the incorporation of 7 % ZnO NPs. The biological properties of the prepared materials have been meticulously investigated. The inhibition zone of CS against C. albicans was 10.66 ± 1.19 mm, while that of the POTFAMA-CS blend was 13.70 ± 1.54 mm. After standard BHT at a concentration of 120 μg/mL, the highest DPPH inhibition percentages belonged to POTFAMA (60.56 %) and POTFAMA-CS (52.99 %). It was detected that the wound closure rates of POTFAMA (17.51 ± 0.75 %) and POTFAMA-CS (15.51 ± 2.52 %) were better than the characteristics of CS wound closure (13.61 ± 2.01 %). The results suggest that POTFAMA-CS may be a good alternative as a wound-healing agent. Furthermore, nanocomposites containing 5 % and 7 % ZnO NPs can be an alternative material in healthcare due to their higher antimicrobial activity.

In Vitro Mucoadhesive Features of Gliadin Nanoparticles Containing Thiamine Hydrochloride

BACKGROUND

Gliadins have aroused significant interest in the last decade as suitable biomaterials for food and pharmaceutical applications. In particular, the oral route is the preferred method of administration for gliadin-based formulations, due to the affinity of this biomaterial for the gut mucosa. However, up to now, this has been demonstrated only by means of in vivo or ex vivo studies.

METHODS

This is why, in this study, various in vitro techniques were employed in order to evaluate the ability of polymeric nanoparticles, made up of a commercial grade of the protein and an etheric surfactant, to interact with porcine gastric mucin. The nanosystems were also used for the encapsulation of thiamine hydrochloride, used as a model of a micronutrient.

RESULTS

The resulting systems were characterized by a mean diameter of ~160-170 nm, a narrow size distribution when 0.2-0.6 mg/mL of thiamine was used, and an encapsulation efficiency between 30 and 45% of the drug initially employed. The incubation of the gliadin nanosystems with various concentrations of porcine gastric mucin evidenced the ability of the carriers to interact with the mucus glycoprotein, showing a decreased Zeta potential after a 4 h incubation (from ~-30 to -40 mV), while demonstrating that the encapsulation of the drug did not affect its bioadhesive features.

CONCLUSIONS

Altogether, these data support the conceivable application of gliadin nanoparticles as formulations for the oral administration of bioactive compounds.

Recent advances in modified chitosan-based drug delivery systems for transmucosal applications: A comprehensive review

Recently, transmucosal drug delivery systems (TDDSs) have been extensively studied because they protect therapeutic agents from degradation; improve drug residence time at the mucosal membranes; and facilitate sustained drug release for a prolonged period. Chitosan is a well-researched polymeric excipient due to its biocompatibility, non-toxicity, biodegradability, mucoadhesive, antimicrobial, and low immunogenicity. Its limited mucoadhesiveness in the physiological environment necessitated its chemical modification. This review highlights the recent advances in the chemical modification of chitosan with various chemical groups to generate various functionalized chitosan derivatives, such as thiolated, acrylated, methacrylated, boronated, catechol, and maleimide-functionalized chitosans with superior mucoadhesive capabilities compared to the parent chitosan. Moreover, it presents the different prepared dosage forms, such as tablets, hydrogels, films, micro/nanoparticles, and liposomes/niosomes for drug administration within various mucosal routes including oral, buccal, nasal, ocular, colonic, intravesical, and vaginal routes. The reported data from preclinical studies of these pharmaceutical formulations have revealed the controlled and target-specific delivery of therapeutics because of their formation of covalent bonds with thiol groups on the mucosal surface. All functionalized chitosan derivatives exhibited long drug residence time on mucosal surfaces and sustainable drug release with excellent cellular permeability, drug efficacy, and biocompatibility. These promising data could be translated from the research laboratories to the clinics with consistent and intensive research effort.

Synthesis of high-performance antibacterial agent based on incorporated vancomycin into MOF-modified lignin nanocomposites

The alarming rise in antibiotic resistance necessitates urgent action, particularly against the backdrop of resistant bacteria evolving to render conventional antibiotics less effective, leading to an increase in morbidity, mortality, and healthcare costs. Vancomycin-loaded Metal-Organic Framework (MOF) nanocomposites have emerged as a promising strategy in enhancing the eradication of pathogenic bacteria. This study introduces lignin as a novel synergistic agent in Vancomycin-loaded MOF (Lig-Van-MOF), which substantially enhances the antibacterial activity against drug-resistant bacteria. Lig-Van-MOF exhibits six-fold lower minimum inhibitory concentration (MICs) than free vancomycin and Van-MOF with a much higher antibacterial potential against sensitive and resistant strains of Staphylococcus aureus and Escherichia coli. Remarkably, it reduces biofilms of these strains by over 85 % in minimal biofilm inhibitory concentration (MBIC). Utilization of lignin to modify surface properties of MOFs improves their adhesion to bacterial membranes and boosts the local concentration of Reactive Oxygen Species (ROS) via unique synergistic mechanism. Additionally, lignin induces substantial cell deformation in treated bacterial cells. It confirms the superior bactericidal properties of Lig-Van-MOF against Staphylococcus species, underlining its significant potential as a bionanomaterial designed to combat antibiotic resistance effectively. This research paves the way for novel antibacterial platforms that optimize cost-efficiency and broaden microbial resistance management applications.

Thiolated chitosan nanoparticles encapsulated nisin and selenium: antimicrobial/antibiofilm/anti-attachment/immunomodulatory multi-functional agent

BACKGROUND

The increase in the resistance of bacterial strains to antibiotics has led to research into the bactericidal potential of non-antibiotic compounds. This study aimed to evaluate in vitro antibacterial/ antibiofilm properties of nisin and selenium encapsulated in thiolated chitosan nanoparticles (N/Se@TCsNPs) against prevalent enteric pathogens including standard isolates of Vibrio (V.) cholerae O1 El Tor ATCC 14,035, Campylobacter (C.) jejuni ATCC 29,428, Salmonella (S.) enterica subsp. enterica ATCC 19,430, Shigella (S.) dysenteriae PTCC 1188, Escherichia (E.) coli O157:H7 ATCC 25,922, Listeria (L.) monocytogenes ATCC 19,115, and Staphylococcus (S.) aureus ATCC 29,733.

METHODS

The synthesis and comprehensive analysis of N/Se@TCsNPs have been completed. Antibacterial and antibiofilm capabilities of N/Se@TCsNPs were evaluated through broth microdilution and crystal violet assays. Furthermore, the study included examining the cytotoxic effects on Caco-2 cells and exploring the immunomodulatory effects of N/Se@TCsNPs. This included assessing the levels of both pro-inflammatory (IL-6 and TNFα) and anti-inflammatory (IL-10 and TGFβ) cytokines and determining the gene expression of TLR2 and TLR4.

RESULTS

The N/Se@TCsNPs showed an average diameter of 136.26 ± 43.17 nm and a zeta potential of 0.27 ± 0.07 mV. FTIR spectroscopy validated the structural features of N/Se@TCsNPs. Scanning electron microscopy (SEM) images confirmed their spherical shape and uniform distribution. Thermogravimetric Analysis (TGA)/Differential Scanning Calorimetry (DSC) tests demonstrated the thermal stability of N/Se@TCsNPs, showing minimal weight loss of 0.03%±0.06 up to 80 °C. The prepared N/Se@TCsNPs showed a thiol content of 512.66 ± 7.33 µmol/g (p < 0.05), an encapsulation efficiency (EE) of 69.83%±0.04 (p ≤ 0.001), and a drug release rate of 74.32%±3.45 at pH = 7.2 (p ≤ 0.004). The synthesized nanostructure demonstrated potent antibacterial activity against various isolates, with effective concentrations ranging from 1.5 ± 0.08 to 25 ± 4.04 mg/mL. The ability of N/Se@TCsNPs to reduce bacterial adhesion and internalization in Caco-2 cells underscored their antibiofilm properties (p ≤ 0.0001). Immunological studies indicated that treatment with N/Se@TCsNPs led to decreased levels of inflammatory cytokines IL-6 (14.33 ± 2.33 pg/mL) and TNFα (25 ± 0.5 pg/mL) (p ≤ 0.0001), alongside increased levels of anti-inflammatory cytokines IL-10 (46.00 ± 0.57 pg/mL) and TGFβ (42.58 ± 2.10 pg/mL) in infected Caco-2 cells (p ≤ 0.0001). Moreover, N/Se@TCsNPs significantly reduced the expression of TLR2 (0.22 ± 0.09) and TLR4 (0.16 ± 0.05) (p < 0.0001).

CONCLUSION

In conclusion, N/Se@TCsNPs exhibited significant antibacterial/antibiofilm/anti-attachment/immunomodulatory effectiveness against selected Gram-positive and Gram-negative enteric pathogens. However, additional ex-vivo and in-vivo investigations are needed to fully assess the performance of nanostructured N/Se@TCsNPs.

Chitosan nanoparticles incorporate with curry leaf essential oil: Physicochemical characterization and in vitro release properties

The use of essential oils as natural antioxidant, antimicrobial and insect repellent agent was limited by the loss of bioactive components especially volatile compounds. This study aimed to improve biological properties of curry leaf essential oil (CLEO) by producing nanometer sized particles through two different synthesis techniques; nanoencapsulation and nanoprecipitation. The methods produced different nanostructures; nanocapsules and nanospheres distinguished by the morphological structure (TEM analysis). Successful loading of CLEO into chitosan nanocarrier was proven by FTIR spectra. Zeta potential values for both nanostructures were more than +30 mV implying their stability against aggregation. CLEO loaded nanocapsules exhibited highest antibacterial properties against Gram-positive bacteria compared to nanospheres. Meanwhile, CLEO loaded nanospheres recorded up until 90.44 % DPPH radical scavenging properties, higher compared to nanocapsules. Both nanostructures demonstrated further improvement in antioxidant and antibacterial activities with the incorporation of higher chitosan concentration. In vitro release analysis indicated that CLEO undergo two-stage discharge mechanism where fast discharge occurred up until 12 h followed by sustained released afterwards. The two synthesis methods applied synergistically with greater chitosan concentration successfully produced nanostructures with >60 % encapsulation efficiency (EE). This concluded that both techniques were reliable to protect the bioactive constituents of CLEO for further used.

Holistic Study Design Following Quality by Design Approach for Fabrication of Hybrid Polymeric Nanoparticulate Based Dry Powders as Carriers for Ciprofloxacin

Resistance to antibiotics such as Ciprofloxacin (CIP) is becoming a critical issue and needs to be addressed globally. CIP is widely used because of manifold uses; however, the long-term therapy poses serious health risks including FDA black box warnings such as tendinitis and peripheral neuropathy. Therefore, nanotechnology-based products can be an effective measure to improve therapeutic outcomes by maintaining the dose at the target site while reducing the dose-dependent toxicity. Biodegradable and biocompatible polymers, Chitosan (CS) and Hyaluronic acid (HA) were used in this work due to their diverse biological characteristics. A simple yet economical ionic gelation method was employed to synthesize nanoparticles with a plexus-like network; nanoplexes, followed by spray-drying to obtain the dry powders to improve stability. Quality by Design (QbD) approach was utilized during the study for robustness and standardization followed by Design of Experiment (DoE) for optimization in a holistic way. The mean particle size of the optimized powder sample was found to be 301.1 nm with a percentage encapsulation efficiency (% EE) of 78.8%. In-vitro dissolution studies corroborated the controlled release of CIP over 48 h. Also, mathematical kinetic modeling was applied to obtain thorough insight into the mechanism of drug release. Moreover, minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were presented to be lower in the case of prepared dry powder as compared to CIP, stating that nanotechnology can improve antimicrobial activity.

Fabrication of blueberry anthocyanins-rich gels based on the apricot polysaccharides with different esterification degrees

To enhance the stability of anthocyanins under conditions such as light, temperature, and pH, an apricot polysaccharide hydrogel for anthocyanins encapsulation was prepared in this study. Apricot polysaccharides with different DEs were prepared by an alkaline de-esterification method. A gel was prepared by mixing the apricot polysaccharides with CaCl2 to encapsulate the anthocyanins; the encapsulation efficiency reached 69.52 ± 0.31 %. Additionally, the gel exhibited favorable hardness (144.17 ± 2.33 g) and chewiness (64.13 ± 1.53 g). Fourier transform infrared (FTIR) and X-ray diffractometer (XRD) spectra confirmed that the formation of the hydrogel primarily relied on electrostatic interactions and hydrogen bonding. Compared with free anthocyanins, it was also found that the gel-encapsulated anthocyanins had a higher retention rate (RR) under different temperatures and light.

Understanding competitive Cu2+ and Zn2+ adsorption onto functionalized cellulose fiber via experimental and theoretical approach

Amidoxime groups were successfully introduced to develop a novel amidoxime-functionalized cellulose fiber (AO-Cell) for absorptive removal of heavy metal ions in wastewater. The chemical structure, and the competitive adsorption of Cu2+ and Zn2+ by AO-Cell were investigated by experiments study, Density functional theory (DFT) and molecular dynamic (MD) simulation. The results showed the N and O atoms in the amidoxime group can spontaneously interact with Cu2+ and Zn2+ through sharing long pair electrons to generate stable coordination structure, which was the dominant adsorption mechanism. Besides, the enlarged surface area, improved hydrophilicity and dispersion offered by AO-Cell facilitate the adsorption process by increasing the accessibility of absorption sites. As results of these synergetic modification, AO-Cell can remain effective in a wide pH range (1-6) and reach adsorption equilibrium within 60 min. At optimal conditions, the achieved theoretical adsorption capacity is as high as 84.81 mg/g for Cu2+ and 61.46 mg/g for Zn2+ in the solution with multiple ions. The competition between Cu2+ and Zn2+ in occupying the absorption sites arises from the difference in the metallic ion affinity and covalent index with the adsorbent as demonstrated by the MD analysis. Importantly, AO-Cell demonstrated favorable recyclability after up to 10 adsorption-desorption cycles.

Multi-dynamic-bond cross-linked antibacterial and adhesive hydrogel based on boronated chitosan derivative and loaded with peptides from Periplaneta americana with on-demand removability

The design and development of a bio-adhesive hydrogel with on-demand removability and excellent antibacterial activities are meaningful to achieve high wound closure effectiveness and post-wound-closure care, which is desirable in clinical applications. In this work, a series of adhesive antioxidant antibacterial hydrogels containing peptides from Periplaneta americana (PAP) were prepared through multi-dynamic-bond cross-linking among 3,4-dihydroxybenzaldehyde (DBA) containing catechol and aldehyde groups and chitosan grafted with 3-carboxy-4-fluorophenylboronic acid (CS-FPBA) to enable the effective adhesion of skin tissues and prevention of bacterial infection of wound. PAP was derived from alcohol-extracted residues generated during the pharmaceutical process, aiming to minimize resource wastage and achieve the high-value development of such a medicinal insect. The hydrogel was prepared by freezing-thawing with no toxic crosslinkers. The multi-dynamic-bond cross-linking of dynamic borate ester bonds and dynamic Schiff base bonds can achieve reversible breakage and re-formation and the adhesive strength of CS-FPBA-DBA-P-gel treated with a 20 % glucose solution dramatically decreased from 3.79 kPa to 0.35 kPa within 10 s. Additionally, the newly developed hydrogel presents ideal biocompatibility, hemostasis and antibacterial activity against Staphylococcus aureus and Escherichia coli compared to commercial chitosan gel (approximately 50 % higher inhibition rate), demonstrating its great potential in dealing with infected full-thickness skin wounds.

Synthesis of novel chitosan/sodium hyaluronate/iridium hydrogel nanocomposite for wound healing application

A novel chitosan/sodium hyaluronate/iridium (CHI/SH/Ir) hydrogel nanocomposite with a unique microstructure containing vertically aligned pores is fabricated via an electrophoresis technique. The formation of orderly vertical pores in CHI/SH/Ir hydrogel nanocomposite is due to the confinement of hydrogen bubbles produced from the water electrolysis during electrophoresis that limits their lateral movement and coalescence. In a wet state, the diameter for the vertical pores is 600-700 μm. With a thickness of 500 μm, the CHI/SH/Ir hydrogel nanocomposite exhibits a porosity of 76.7 % and a water uptake of 350 %. Its tensile strength is almost doubled to 8.7 MPa, as compared to that of counterpart without the addition of iridium. In CHI/SH/Ir hydrogel nanocomposite, the iridium nanoparticles are homogeneously distributed with an average size of 3 nm. The CHI/SH/Ir electrophoresis suspension exhibits a negligible cytotoxicity. In cell migration test using the human keratinocytes HaCaT cells, the CHI/SH/Ir hydrogel nanocomposite reveals a relative migration of 122.15 ± 9.02 % (p < 0.001) as compared to the blank sample. The presence of vertically aligned pores with the use of SH and iridium nanoparticles indicates a promising opportunity in wound healing application.

Optimized mucoadhesive niosomal carriers for intranasal delivery of carvedilol: A quality by design approach

Carvedilol (CV), a β-blocker essential for treating cardiovascular diseases, faces bioavailability challenges due to poor water solubility and first-pass metabolism. This study developed and optimized chitosan (CS)-coated niosomes loaded with CV (CS/CV-NS) for intranasal (IN) delivery, aiming to enhance systemic bioavailability. Utilizing a Quality-by-Design (QbD) approach, the study investigated the effects of formulation variables, such as surfactant type, surfactant-to-cholesterol (CHOL) ratio, and CS concentration, on CS/CV-NS properties. The focus was to optimize specific characteristics including particle size (PS), polydispersity index (PDI), zeta potential (ZP), entrapment efficiency (EE%), and mucin binding efficiency (MBE%). The optimal formulation (Opt CS/CV-NS), achieved with a surfactant: CHOL ratio of 0.918 and a CS concentration of 0.062 g/100 mL, using Span 60 as the surfactant, exhibited a PS of 305 nm, PDI of 0.36, ZP of + 33 mV, EE% of 63 %, and MBE% of 57 %. Opt CS/CV-NS was characterized for its morphological and physicochemical properties, evaluated for stability under different storage conditions, and assessed for in vitro drug release profile. Opt CS/CV-NS demonstrated a 1.7-fold and 4.8-fold increase in in vitro CV release after 24 h, compared to uncoated CV-loaded niosomes (Opt CV-NS) and free CV, respectively. In vivo pharmacokinetic (PK) study, using a rat model, demonstrated that Opt CS/CV-NS achieved faster Tmax and higher Cmax compared to free CV suspension indicating enhanced absorption rate. Additionally, Opt CV-NS showed a 1.68-fold higher bioavailability compared to the control. These results underscore the potential of niosomal formulations in enhancing IN delivery of CV, offering an effective strategy for improving drug bioavailability and therapeutic efficacy.

Enhanced oral delivery of hesperidin-loaded sulfobutylether-β-cyclodextrin/chitosan nanoparticles for augmenting its hypoglycemic activity: in vitro-in vivo assessment study

Hesperidin (Hsd), a bioactive phytomedicine, experienced an antidiabetic activity versus both Type 1 and Type 2 Diabetes mellitus. However, its intrinsic poor solubility and bioavailability is a key challenging obstacle reflecting its oral delivery. From such perspective, the purpose of the current study was to prepare and evaluate Hsd-loaded sulfobutylether-β-cyclodextrin/chitosan nanoparticles (Hsd/CD/CS NPs) for improving the hypoglycemic activity of the orally administered Hsd. Hsd was first complexed with sulfobutylether-β-cyclodextrin (SBE-β-CD) and the complex (CX) was found to be formed with percent complexation efficiency and percent process efficiency of 50.53 ± 1.46 and 84.52 ± 3.16%, respectively. Also, solid state characterization of the complex ensured the inclusion of Hsd inside the cavity of SBE-β-CD. Then, Hsd/CD/CS NPs were prepared using the ionic gelation technique. The prepared NPs were fully characterized to select the most promising one (F1) with a homogenous particle size of 455.7 ± 9.04 nm, a positive zeta potential of + 32.28 ± 1.12 mV, and an entrapment efficiency of 77.46 ± 0.39%. The optimal formula (F1) was subjected to further investigation of in vitro release, ex vivo intestinal permeation, stability, cytotoxicity, and in vivo hypoglycemic activity. The results of the release and permeation studies of F1 manifested a modulated pattern between Hsd and CX. The preferential stability of F1 was observed at 4 ± 1 °C. Also, the biocompatibility of F1 with oral epithelial cell line (OEC) was retained up to a concentration of 100 µg/mL. After oral administration of F1, a noteworthy synergistic hypoglycemic effect was recorded with decreased blood glucose level until the end of the experiment. In conclusion, Hsd/CD/CS NPs could be regarded as a hopeful oral delivery system of Hsd with enhanced antidiabetic activity.

Advancements in Chitosan-Based Nanoparticles for Pulmonary Drug Delivery

The evolution of respiratory diseases represents a considerable public health challenge, as they are among the leading causes of death worldwide. In this sense, in addition to the high prevalence of diseases such as asthma, chronic obstructive pulmonary disease, pneumonia, cystic fibrosis, and lung cancer, emerging respiratory diseases, particularly those caused by members of the coronavirus family, have contributed to a significant number of deaths on a global scale over the last two decades. Therefore, several studies have been conducted to optimize the efficacy of treatments against these diseases, focusing on pulmonary drug delivery using nanomedicine. Thus, the development of nanocarriers has emerged as a promising alternative to overcome the limitations of conventional therapy, by increasing drug bioavailability at the target site and reducing unwanted side effects. In this context, nanoparticles composed of chitosan (CS) show advantages over other nanocarriers because chitosan possesses intrinsic biological properties, such as anti-inflammatory, antimicrobial, and mucoadhesive capacity. Moreover, CS nanoparticles have the potential to enhance drug stability, prolong the duration of action, improve drug targeting, control drug release, optimize dissolution of poorly soluble drugs, and increase cell membrane permeability of hydrophobic drugs. These properties could optimize the performance of the drug after its pulmonary administration. Therefore, this review aims to discuss the potential of chitosan nanoparticles for pulmonary drug delivery, highlighting how their biological properties can improve the treatment of pulmonary diseases, including their synergistic action with the encapsulated drug.